PHIO: Phio Pharmaceuticals Corp. Stock

by  •  • Comments Off on PHIO: Phio Pharmaceuticals Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.19
Enterprise Value ($M) -5.30
Book Value ($M) 7.73
Book Value / Share 1.68
Price / Book 0.41
NCAV ($M) 7.69
NCAV / Share 1.67
Price / NCAV 0.42

Profitability (mra)
Return on Invested Capital (ROIC) -1.38
Return on Assets (ROA) -1.12
Return on Equity (ROE) -1.48

Liquidity (mrq)
Quick Ratio 5.71
Current Ratio 5.71

Balance Sheet (mrq) ($M)
Current Assets 9.32
Assets 9.36
Liabilities 1.63
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -10.62
Net Income -10.83
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -10.75
Cash from Investing -0.01
Cash from Financing 7.41

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-06 13G/A Intracoastal Capital, Llc 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-11 10-Q Quarterly Report on Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 28,330 4,821 587.64
2024-04-25 57,516 23,752 242.15
2024-04-24 21,252 11,055 192.24
2024-04-23 169,907 48,247 352.16

(click for more detail)

Similar Companies
PALI – Palisade Bio, Inc. PCSA – Processa Pharmaceuticals, Inc.
PDSB – PDS Biotechnology Corporation PIRS – Pieris Pharmaceuticals, Inc.
PLUR – Pluri Inc.


Financial data and stock pages provided by
Fintel.io